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Abstract
Background: Recurrent colic and unexplained weight loss despite good appetite and adequate feeding and
management practices are common conditions in the horse. However, little information has been published
on the systematic diagnostic evaluation, response to treatment, prognostic factors or outcome of either presentation.
The aims of this study were to 1) identify possible prognostic indicators and 2) report the short- and long-term response
to treatment with corticosteroid therapy of a variety of horses with a presumptive diagnosis of inflammatory bowel
disease (IBD).
Thirty-six horses with a history of recurrent colic and/or unexplained weight loss were screened with a detailed clinical,
clinicopathological and diagnostic imaging examination. Twenty horses were subsequently selected that had findings
consistent with inflammatory bowel disease based on the fulfilment of one or more of the following additional inclusion
criteria: hypoproteinaemia, hypoalbuminaemia, malabsorption, an increased intestinal wall thickness on ultrasonographic
examination or histopathological changes in rectal biopsy. These 20 horses were treated with a standardized larvicidal
anthelmintic regime and a minimum of three weeks of corticosteroid therapy.
Results: The initial response to treatment was good in 75% (15/20) of horses, with a 3-year survival rate of 65% (13/20).
The overall 3-year survival in horses that responded to initial treatment (12/15) was significantly higher (P = 0.031) than in
those that did not respond to initial treatment (1/5). The peak xylose concentration was significantly (P = 0.048) higher in
survivors (1.36 ± 0.44 mmol/L) than non-survivors (0.94 ± 0.36 mmol/L).
Conclusions: The overall prognosis for long-term survival in horses with a presumptive diagnosis of IBD appears
to be fair to moderate, and the initial response to anthelmintic and corticosteroid therapy could be a useful
prognostic indicator. The findings of the present study suggest that a low peak xylose concentration in absorption
testing is associated with a less favourable prognosis, supporting the use of this test.
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Background
Recurrent colic and weight loss are conditions in the horse
that can present either in combination or as separate
problems. Numerous reasons exist for both presentations,
including management and feeding practices, intestinal
diseases such as parasitism and neoplasias [1,2] and
various non-intestinal diseases [1]. Inflammatory bowel
disease (IBD) is another potential cause of both recurrent
colic and weight loss that has been histologically classified
into the different subtypes of lymphocytic-plasmacytic
enterocolitis (LPE), granulomatous enteritis (GE), mul-
tisystemic eosinophilic epitheliotropic disease (MEED),
diffuse eosinophilic enteritis (DEE) and idiopathic focal
eosinophilic enteritis (IFEE) [3-6]. IBD has previously
been reported to cause a variety of clinical presentations,
from malabsorption and weight loss to diarrhoea and
colic. In particular, eosinophilic enteritis has been reported
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to cause colic, while weight loss, hypoproteinaemia, hypo-
albuminaemia and carbohydrate malabsorption have all
been associated with LPE, MEED and GE [4,5].
Currently, diagnostic evaluation of equine gastrointestinal
disease includes clinical and dental examination, routine
haematology and biochemistry. Where these fail to identify
the pathology, abdominal ultrasonography, carbohydrate
absorption tests and histopathology of rectal mucosal
biopsies may be useful [1]. The use of rectal mucosal
biopsies is appealing, as they are minimally invasive
and easy to obtain with no specialized equipment, and
histopathology has been demonstrated to be potentially
useful in determining the underlying disease process
[7,8]. Alternatively, gastric and duodenal mucosal biopsies
can be taken via endoscopy, or full thickness intestinal
biopsies can be taken via exploratory celiotomy. However,
these require specialized equipment that is not always
available or affordable, which limits their usefulness.
Indirect tests of intestinal function, such as D-xylose
and glucose absorption, have been described in the horse.
These tests can provide useful information, particularly on
small intestinal function. The D-xylose absorption test is
considered more accurate than the glucose absorption
test, because D-xylose is not normally present in the horse
and the serum concentration of D-xylose is not affected
by factors such as metabolic status, stress or excitement,
in contrast to glucose [1,9-13].
The retrospective evaluation of horses with weight loss
has recently been reported by Metcalfe et al. [14], but
at present there is a paucity of systematic prospective
studies evaluating the results, and identification of risk
factors, from routine examination (history and clinical
evaluation), measurement of carbohydrate absorption,
abdominal ultrasonography and histopathological find-
ings from rectal biopsy in horses with recurrent colic
or weight loss. Furthermore, limited information exists
regarding the treatment response of various enteropathies
to corticosteroid therapy, although the prognosis of IBD is
generally regarded as guarded to poor [4,8,15-17]. Finally,
the long-term prognosis for horses with a presumptive
diagnosis of IBD that respond to initial treatment with
corticosteroid therapy has not yet been reported.
The aims of the study were to 1) identify prognostic in-
dicators and 2) report the short- and long-term response
of a variety of horses with signs suggestive of IBD to treat-
ment with corticosteroid and anthelmintic therapy.
Methods
Horses
The prospective cohort clinical study was performed
between 1 May 2004 and 31 December 2005 at the
Equine Hospital of the Faculty of Veterinary Medicine,
University of Helsinki, and Hyvinkää Equine Hospital,
Finland. Long-term survival was reported for a 3-year
period following the discontinuation of treatment. Horses
with a history of recurrent colic, as defined by at least two
episodes of colic requiring veterinary attention during
the preceding 12 months [18], or anamnestic information
regarding unexplained weight loss or an inability to gain
weight despite adequate feeding and management practices,
were considered eligible for initial screening for inclusion
in the study. Furthermore, to be eligible for screening,
horses were required to be ≥2 years of age and have
received adequate feeding, deworming and dental care
as determined by the examining veterinarian. Horses
that presented with acute colic or that had previously
undergone colic surgery were excluded, as were horses
receiving corticosteroid therapy at the time of assessment
or in the six months preceding assessment. The study was
approved by the Ethical Committee of the University of
Helsinki (UH number 89–04). Informed consent from the
owner, or the trainer acting as an agent for the owner, was
obtained at the time of enrolment in the study.
Diagnostic evaluation
A thorough history was obtained, including signalment and
management. The initial examination included a basic clin-
ical examination, determination of body weight with scales,
lameness examination, oral examination, palpation per
rectum, a complete blood count, fibrinogen measurement,
serum biochemistry (globulins were counted by subtracting
serum albumin from total protein), thoracic and abdominal
radiography, transabdominal ultrasonography, peritoneal
fluid analysis, urinalysis, a faecal flotation test for parasites,
a D-xylose absorption test [19], gastroscopy and duode-
noscopy [20], as well as a rectal mucosal biopsy and
histopathology, as described by Lindberg et al. [7]. The
body condition score was determined by two clinicians,
as described by Henneke et al. [21], and ranged from 1
to 9, where 1 was extremely emaciated and 9 extremely
overweight.
In addition to having fulfilled the criteria for initial
screening to be included in the final study, horses had
to fulfil at least one of the following criteria: hypopro-
teinaemia (defined as a serum total protein concentration
of less than 54 g/L), hypoalbuminaemia (defined as a
serum albumin concentration of less than 28 g/L), a peak
plasma xylose concentration of less than 1.33 mmol/L [1],
increased intestinal wall thickness (>4 mm) according to
ultrasonographic assessment [22] or changes in the rectal
mucosal biopsy suggestive of IBD. Horses were excluded
from the final study if another, non-IBD cause of the pre-
senting clinical signs was identified. This included horses
with significant intestinal sand accumulation [23], severe
gastric ulceration (grades 3–4/4), evidence of infectious
disease as indicated by changes in haematology and/or
fibrinogen, and serum biochemical changes consistent
with renal or hepatic failure.
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Therapeutic protocols
All horses included in the study were initially treated
with the same protocol. Anthelmintics were started with
five consecutive days of fenbendazole (Axilur, MSD Animal
Health) 10 mg/kg per os (PO) once daily, followed by a
single dose of ivermectin at 0.2 mg/kg and praziquantel
at 1 mg/kg (Equimax, Virbac de Portugal) PO on day 6.
Prednisolone (Prednisolon 40 mg, Leiras) at 1 mg/kg PO
once daily was started on day 1 and continued until the first
follow-up examination was performed, after approximately
three weeks of treatment.
On follow-up, the horses were clinically evaluated, body
weight was determined by scales, and the tests previously
identified as abnormal were repeated. Further medication
was decided at the treating clinician’s discretion according
to the findings from the follow-up examination and based
on the following guidelines: if the original complaint(s)
(weight loss and/or recurrent colic) had clinically improved
and the results from any/all previously abnormal tests
(D-xylose absorption, histopathology of rectal mucosal
biopsy, intestinal wall thickness as determined by ultrason-
ography, hypoalbuminaemia and/or hypoglobulinaemia)
had improved or normalised, corticosteroid therapy was
gradually tapered and then discontinued. Horses that
had shown minimal or no improvement were changed
to dexamethasone (Dexametason 1.5 mg, Orion Pharma)
at 0.1 mg/kg PO once daily with subsequent treatment at
the treating clinician’s discretion. Horse owners were
interviewed by telephone about their horse’s condition
and the possible reoccurrence of any symptoms approxi-
mately 3 and 6 months following the discontinuation of
treatment. The national horse register database was used
to trace horses for long-term survival at three years after
the discontinuation of treatment.
Statistical analysis
The Shapiro-Wilk test was used to evaluate whether the
data were normally distributed. Pearson correlations were
calculated between the normally distributed parameters,
and the two-tailed Student’s t-test was used for compari-
sons between horses that were or were not alive three
years after treatment. Spearman's correlation and the
Mann–Whitney U-test were used for nonparametric
data. A two-tailed Fischer’s exact test was used to com-
pare the response to initial treatment between survivors
and non-survivors. Significance was set at P < 0.05. Post-
hoc power calculations were performed using online data
management software [24].
Results
Horses
Thirty-six client-owned horses met the criteria for initial
screening, with 20 horses subsequently included in the
final study. Five of the 20 horses included in the final
study had a primary complaint of recurrent colic, nine
horses were included due to weight loss and six
presented with a history of both recurrent colic and
weight loss.
Diagnostic evaluation
Histopathology of the rectal mucosal biopsy was con-
sidered abnormal in 5/13 and 3/7 of survivors and non-
survivors, respectively. Intestinal thickening (>4 mm),
as determined by ultrasound, was present in 6/13 and
4/7 of survivors and non-survivors, respectively. These
proportions did not significantly differ between survivors
and non-survivors. The proportion of horses with a peak
D-xylose concentration below the normal threshold of
1.33 mmol/L did not differ between survivors (8/13) and
non-survivors (6/7). However, the mean peak D-xylose
concentration was significantly higher in survivors (1.36 ±
0.44) than non-survivors (0.94 ± 0.36) (P = 0.048). Faecal
flotation was negative in all horses. The presumptive
diagnosis of the IBD subtype was based on the history,
clinical presentation and the results of the diagnostic
work-up, with particular emphasis placed on histo-
pathological changes in the rectal mucosal biopsy.
Treatment and follow up
Treatment was attempted in all horses and all returned
for re-evaluation at approximately three weeks. Five horses
failed to demonstrate satisfactory improvement in their
clinical or clinicopathological parameters in the first weeks
and were changed to dexamethasone therapy as outlined
above. The remaining 15 horses were considered to have
improved and corticosteroid therapy was tapered and
discontinued.
Seven of the 20 horses died during the three-year follow-
up period, with death related to the original problem of
weight loss or recurrent colic in all but one horse (Table 1).
Of these seven horses, three had initially responded well
to treatment, while four had responded poorly. The overall
3-year survival rate in horses that responded to initial
treatment (12/15: 80%) was significantly higher (P = 0.031)
than in horses that did not respond to initial treatment
and were subsequently changed to dexamethasone
(1/5: 20%). Five of the non-surviving horses underwent
post-mortem examination, and in four of these horses
this examination confirmed the presumptive diagnosis
of inflammatory bowel disease. Table 2 presents the age,
body composition score, serum protein, albumin and
globulin concentration, and peak D-xylose concentra-
tions at enrolment, as well as the length of treatment
for survivors and non-survivors. The peak D-xylose
concentration correlated significantly with serum total
protein (r = 0.45, P < 0.001) and globulin concentrations
(r = 0.61, P = 0.005), but not with serum albumin concen-
tration (r = −0.19, P = 0.41). The power of the study to
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detect a difference between survivors and non-survivors
was 49.1%, 12.1% and 62.6% for serum total protein, serum
albumin and serum globulin concentrations, respectively.
Discussion
In the present study, the response to anthelmintic and
corticosteroid therapy over a three-week period was
demonstrated to be a useful predictor of the outcome in
horses with a presumptive diagnosis of IBD. The long-term
prognosis for horses in the present study was fair to
moderate, with 65% of the horses surviving at least
three years. This is in contrast to the current literature,
in which the response of IBD to corticosteroid treatment
is generally considered to be poor [4,8,16,17]. Possible
reasons for this discrepancy, including case selection,
case definition and the role of anthelmintic therapy in
the outcome, warrant discussion.
Anthelmintic therapy was performed regardless of the
negative results of faecal analysis, as the faecal flotation
test underestimates the parasite burden when there are
more larval stages than adults, and is unable to detect
encysted cyathostomes [25]. Furthermore, it has been
postulated that endoparasites may have a role in triggering
the disease process of inflammatory bowel disease [26-28].
As such, the treatment of endoparasitism in suspected
IBD cases is logical. Fenbendazole was chosen as the
therapeutic agent, as it is efficacious against encysted cya-
thostomes when used as described above [29], and there
was no known resistance towards fenbendazole in the
geographical area in which the study was performed.
Although both hospitals involved in the study were
referral centres, the case load at both facilities is a broad
representation of the clinical spectrum, with a large
proportion of the case load effectively comprising first
opinion cases. The inclusion of first opinion cases may
at least partly explain the better outcome observed in
the study than previously reported. Similarly, most of
the cases in the present study that were presumptively
diagnosed with IBD were less severely affected than the
confirmed cases described in the literature [8,30,31].
This may have biased the population studied towards
animals that were more likely to respond to treatment
than those previously reported from true referral popu-
lations [4,8,16,17]. Alternatively, it is possible that the
Table 1 Presumptive IBD subtype (based on the clinical picture and findings from the diagnostic work-up) and
post-mortem diagnoses (when available) of non-survivors (n = 7), and length of survival after the discontinuation
of treatment
Presumptive diagnosis Time when died/euthanized Indication Post-mortem diagnosis
Lymphocytic-plasmacytic enteritis During the treatment (day 26) Progressive weight loss,
animal welfare
Lymphocytic-plasmacytic enteritis
Eosinophilic enterocolitis 2 days after discontinuing the treatment Colic Idiopathic small intestinal
muscular hypertrophy
Eosinophilic enterocolitis 22 days after discontinuing the treatment Death due to acute cardiac failure Eosinophilic enterocolitis
Acute cardiac failure
Eosinophilic enterocolitis 30 days after discontinuing the treatment Colic Not performed
Lymphocytic-plasmacytic enteritis 120 days after discontinuing the treatment Progressive weight loss Lymphocytic-plasmacytic enteritis
Eosinophilic enterocolitis 7 months 13 days after discontinuing
the treatment
Recurrent colic Not performed
Eosinophilic enterocolitis 1 year 8 months after discontinuing
the treatment
Recurrent colic Eosinophilic enterocolitis
Table 2 Means ± SD (min–max) of the age, body composition score, serum protein, albumin and globulin concentrations,
and peak xylose concentration, the numbers of horses with each abnormal finding and the length of treatment in
long-term (3 years) survivors and non-surviving horses
Survivors (n = 13) Non-survivors (n = 7) P
Age (years) 9.7 ± 4.5 (3–17) 10.0 ± 5.3 (4–20) 0.893
Body score 3.9 ± 1.4 (2–7)1 3.6 ± 0.5 (3–4) 0.598
S-protein (g/L) 61.6 ± 8.3 (44.2–77.2) 53.4 ± 11.9 (30.6–69.6) 0.086
S-albumin (g/L) 33.1 ± 5.5 (20.3–40.8) 31.4 ± 8.7 (14.7–39.4) 0.843
S-globulin (g/L) 28.5 ± 7.5 (21.3–46.4) 22.0 ± 6.8 (15.5–30.9) 0.073
Peak xylose (mmol/L) 1.36 ± 0.44 (0.85–2.27) 0.94 ± 0.36 (0.27–1.37) 0.048
Length of treatment (d) 51.1 ± 13.2 (22–69) 71.1 ± 32.8 (43–120)2 0.065
1Data missing from two surviving horses.
2One horse is not included in this calculation as it was euthanized on humane grounds after 26 days of treatment.
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response to treatment seen in some cases was due to
the larvicidal anthelmintic treatment that was included
in the protocol rather than the corticosteroids. All
horses in the present study had a history of adequate
anthelmintic treatment, and no significant parasite burdens
were detected on faecal analysis, reducing the likelihood
that endoparasites were a major factor. However, neither
factor excludes parasitism as a potential diagnosis, espe-
cially cyathostomiasis, as discussed above.
The authors recognise that the definition of IBD used
in this study is broad and may inadvertently encompass
other disease conditions such as low-grade cyathostomiasis.
However, despite the limitations in ruling out parasitism
and achieving a definitive diagnosis, we believe that present
study accurately reflects the clinical presentation of weight
loss and recurrent colic seen in practice. As such, we argue
that the results of the study are applicable to the clinical
setting. The finding that the response to initial treatment is
predictive of long-term survival is of particular importance
and direct clinical relevance. The development of clearer
guidelines for the diagnosis of IBD would be beneficial in
defining inclusion criteria for future prospective studies.
The results of this study support the use of the D-xylose
test in the diagnostic evaluation of recurrent colic and
weight loss, with inadequate D-xylose absorption the only
significant clinicopathological prognosticator of survival
identified. Importantly, the horse’s diet can influence
the D-xylose curve, with horses fed a high-energy diet
reported to have lower peak plasma concentrations
[32]. Additionally, prolonged fasting (72–96 h) can lower
the peak concentration of D-xylose [33] and warrants
consideration in the interpretation of the test results.
In the present study, all the horses were fed in a similar
manner, with none receiving a high-energy diet, and no
horses were fasted for a prolonged period before testing.
As such, these factors are unlikely to have influenced the
accuracy of the test.
In the present study, peak D-xylose concentrations
were not associated with the serum albumin concentration,
but were associated with the serum globulin concentration.
This contradicts the existing literature, wherein it is com-
monly assumed that horses with malabsorption will also
have a low serum albumin concentration, since the rate
of albumin production is slower compared to globulin
production [34]. This assumption is supported by a recent
study in which both hypoproteinaemia and hypoalbumi-
naemia, but not hypogammaglobulinaemia, were associ-
ated with non-survival in horses with unexplained weight
loss [14]. The small number of horses in the present study
is a significant limitation, and the power of the study to
detect a difference between survivors was only 49.1%,
12.1% and 62.6% for serum total protein, serum albumin
and serum globulin concentrations, respectively. As such,
the risk of a type II error was relatively high in the present
study. The trend towards a difference between survivors
and non-survivors in serum total protein, which is consis-
tent with a recent report [14], and in serum globulins,
which has not previously been reported, warrants consi-
deration in the interpretation of results, although care
should be taken in drawing firm conclusions.
Interestingly, despite hypoalbuminaemia previously be-
ing identified as a significant risk factor for non-survival
in a previous study [14], the data from the present study
do not support a similar conclusion. The reasons for this
discrepancy are not immediately apparent. Both the
present study and the previous study by Metcalfe et al.
[14] reporting the outcome of chronic gastrointestinal
disease were limited by small numbers. The risk of both
type I and type II statistical errors increases as a function
of decreasing sample size, and consequentially power
[35]. As such, the inability to find an association between
serum albumin and the outcome in the present study, or
the association previously reported by Metcalfe et al. [14],
could be erroneous due to a type II or type I statistical
error, respectively. Considering this, a larger prospective
clinical study is warranted to further investigate the rela-
tionship between clinicopathological parameters and the
outcome before any firm conclusions can be drawn. How-
ever, combining the results of the present study with the
previous observations of Metcalfe et al. [14], serum total
protein appears to be the most consistent clinicopatholo-
gical predictor of the outcome.
Histopathological changes in the rectal biopsy were
detected in less than half of the cases studied, but the
findings of the present study suggest that when present,
changes in rectal mucosal histopathology were in line
with subsequent post-mortem findings. This supports
their use in the diagnostic evaluation of weight loss and/
or recurrent colic cases.
Conclusions
The overall prognosis for long-term survival in horses
with a presumptive diagnosis of IBD appears to be fair
to moderate. The initial response to anthelmintic and
corticosteroid therapy could be a useful prognostic indi-
cator, and the findings of the present study suggest that
a low peak xylose concentration in absorption testing is
associated with a less favourable prognosis, supporting
the use of this test.
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